Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment

European Journal of Internal Medicine

Volumn 20, Issue 4, 2009, Pages 369-372

  Onal, Ibrahim Koral ^a   Altun, Bulent ^a   Onal, Eda Demir ^a   Kirkpantur, Alper ^a   Gul Oz, Serife ^a   Turgan, Cetin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Hypertension; Matrix metalloproteinases; Renin Angiotensin System

Indexed keywords

ALBUMIN; CANDESARTAN; GELATINASE B; LORATADINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; MALE; URINALYSIS; URINARY EXCRETION;

ADULT; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; COLLAGEN; ELASTIN; EXTRACELLULAR MATRIX; FEMALE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 67349238290     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2008.10.003     Document Type: Article

References (27)

1. Chobanian A.V., Bakris G.L., Black H.R., et al. National heart, lung, and blood institute Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure; national high blood pressure education program coordinating committee: The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 Report. JAMA 289 (2003) 2560-2572
2. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):1-266.
3. Intengan H.D., and Schiffrin E.L. Structure and mechanical properties of resistance arteries in hypertension. Hypertension 36 (2000) 312-318
4. Tayebjee M.H., Nadar S.K., MacFadyen R.J., and Lip G.Y. Tissue inhibitor of MMP-1 and MMP-9 levels in patients with hypertension. Relationship to tissue Doppler indices of diastolic relaxation. AJH 17 (2004) 770-774
5. Schieffer B., Bunte C., Witte J., et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44 (2004) 362-368
6. Tayebjee M.H., Lim H.S., Macfadyen R.J., and Lip G.Y. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes. Effect of 1 years cardiovascular risk reduction therapy. Diabetes Care 27 (2004) 2049-2051
7. Li-Saw-Hee F.L., Edmunds E., Blann A.D., Beevers D.G., and Lip G.Y. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 75 (2000) 43-47
8. Li H., Simon H., Bocan T.M., and Peterson J.T. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res 46 (2000) 298-306
9. Bolbrinker J., Markovic S., Wehland M., Melenhorst W.B., van Goor H., and Kreutz R. Expression and response to ACE-inhibition of matrix metalloproteinases-2 and -9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension. J Pharmacol Exp Ther 316 (2006) 8-16
10. Asanuma K., Magid R., Johnson C., Nerem R.M., and Galis Z.S. Uniaxial strain upregulates matrix-degrading enzymes produced by human vascular smooth muscle cells. Am J Physiol 284 (2003) 1778-1784
11. O Callaghan J.C., and Williams B. Mechanical strain-induced extracellular matrix production by human vascular smooth muscle cells: role of TGF-β1. Hypertension 36 (2000) 319-324
12. Donnelly R., Collinson D.J., and Manning G. Hypertension, matrix metalloproteinases and target organ damage. J Hypertens 21 (2003) 1627-1630
13. Gunja-Smith Z., Morales A.R., Romanelli R., and Woessner Jr. J.F. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Am J Pathol 148 (1996) 1639-1648
14. Gunja-Smith Z., Morales A.R., Romanelli R., and Woessner Jr. J.F. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross links. Am J Pathol 148 (1996) 1345-1350.
15. Eddy A.A., Kim H., Lopez-Guisa J., Oda T., and Soloway P.D. Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective. Kidney Int 58 (2000) 618-628
16. Li X., Meng Y., Yang X.S., Mi L.F., and Cai S.X. ACEI attenuates the progression of CCl4- induced rat hepatic fibrogenesis by inhibiting TGF-beta1, PDGF-BB, NF-kappaB and MMP- 2,9. World J Gastroenterol 11 (2005) 4807-4811
17. Williams R.N., Parsons S.L., Morris T.M., Rowlands B.J., and Watsons S.A. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol 31 (2005) 1042-1050
18. Jesmin S., Sakuma I., Hattori Y., and Kitabatake A. Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats. Arterioscler Thromb Vasc Biol 23 (2003) 2021-2026
19. Gurjar M.V., Sharma R.V., and Bhalla R.C. eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Bio 19 (1999) 2871-2877
20. Dollery C.M., McEwan J.R., and Henney A.M. Matrix metalloproteinases and cardiovascular disease. Circ Res 77 (1995) 863-868
21. Laviades C., Varo N., Fernández J., Mayor G., Gil M.J., Monreal I., et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98 (1998) 535-540
22. Ergul A., Dobos V.P., Hutchinson J., Franco J., and Anstadt M.P. Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients. AJH 17 (2004) 775-782
23. Liebetrau M., Burggrafb D., Wunderlichb N., Jager G., Linz W., and Hamann G.F. ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats. Neuroscience Letters 376 (2005) 205-209
24. Yasmin, Mc Eniery C.M., Wallace S., et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 25 (2005) 372
25. Zervoudaki A., Economou E., Pitsavos C., et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 17 (2003) 119-124
26. Verdecchia P., and Reboldi G.P. Hypertension and microalbuminuria: the new detrimental duo. Blood Pres 13 (2004) 198-211
27. Ebihara I., Nakamura T., Shimada N., and Koide H. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis 32 (1998) 544-550